[ad_1]
Image source,Reuters
China National Pharmaceutical Group (Sinopharm) China Bio-Beijing Company said on December 30 that its new coronavirus vaccine has a 79.34% protective effect against the disease caused by the new coronavirus infection (COVID-19).
China Bio-Beijing Company announced on its website that it has submitted a request for conditional listing to the State Food and Drug Administration. .
Public information shows that there are currently five vaccines in China that have entered phase III clinical trials, including adenovirus vector vaccines from the Academy of Military Sciences and Kangsino, recombinant protein vaccines from the Institute of Microbiology of the Academy of Sciences. of China and Anhui Zhifei, as well as the Wuhan Institute of Biology and Beijing Biology. The vaccine, etc.
Provisional data from phase III trial
The announcement indicated that the results of the interim analysis of the phase III clinical trial of this new coronavirus-inactivated vaccine showed that the safety of the vaccine is good after vaccination. After two injections, the vaccinated bacteria produce high-titer antibodies and the positive conversion rate of neutralizing antibodies is 99.52%. , The protective efficacy of the vaccine against diseases infected by the new coronavirus is 79.34%.
Image source,Reuters
From these data, the effectiveness of the Sinopharm vaccine is less than the 95% protection rate of the Moderna and Pfizer / BioNTech vaccines that have been used in other countries, but is greater than the effectiveness of the vaccine from the World Health Organization against the new crown. % Limit.
China Bio-Beijing Company stated in the announcement that the result of this data complies with the relevant technical standards of the World Health Organization and the relevant standards in the “Guidelines for the Clinical Evaluation of New Preventive Vaccines for Coronavirus (Trial) “issued by the State Food and Drug Administration.
The announcement did not reveal further data from the phase III clinical trial.
Sinopharm vaccination status
In China’s emergency vaccination plan, nearly 1 million people have been vaccinated with the new corona vaccine from Sinopharm. Sinopharm said it has not received a report of a serious adverse reaction, just a few minor symptoms.
Liu Jingzhen, secretary of the Party Committee and chairman of the Sinopharm Group, presented to the Chinese media in August this year that Sinopharm sought to make advances in both inactivated vaccines and genetically engineered subunit vaccines in terms of new corona vaccines. Parallel research on the route of inactivated vaccines is being conducted by the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products of China National Pharmaceutical Group Co., Ltd., while the Sinopharm Group’s National Biotechnology Institute of China is conducting research on the genetically engineered subunit vaccine.
Image source,fake images
China’s Crown Vaccine Development Is Taking A More Traditional Route
He introduced that an inactivated vaccine is simply to first isolate the virus strain. “Just like choosing a ‘seed’, you have to choose a good ‘seed’; after that you can reproduce and cultivate, like magnify dozens of times, hundreds of times, etc., and then kill these live viruses so that lose their infectivity and replicate power, but at the same time it retains its part of the function of stimulating the body’s immune response, and finally it becomes a vaccine through purification and other processes “, he told the Chinese state media at that time” Guangming Daily “.
Liu Jingzhen later stated publicly in November that there were 56,000 people who had left after being injected with the Sinopharm vaccine, including foreign construction personnel, diplomats and students who went to more than 150 countries around the world. “There has been no case of infection.”
He also stated that Sinopharm vaccines have already conducted international phase III clinical trials in 10 countries, including the United Arab Emirates, Bahrain, Egypt, Jordan, Peru and Argentina. Blood collection 14 days after completion of the two injections showed “very good” performance.
On December 9, the UAE Ministry of Health and Prevention announced the approval of the new corona vaccine developed by the Sinopharm Beijing Institute of Biological Products to be marketed in the country.
Liu Jingzhen said in November that dozens of countries have already asked Sinopharm Group to buy the new corona vaccine. Once the listing is approved, the Chinese vaccine will be officially released on the international market. The production capacity of China’s new crown vaccine next year is expected to reach more than 1 billion doses, which can ensure a safe and adequate vaccine supply.
What about other vaccines?
At present, the vaccines that have been put into use in European and American countries are mainly Modena and Pfizer / BioNTech, and the effective rate is said to be around 95%.
On December 30, the new corona vaccine developed by the University of Oxford in the UK was approved for use in the UK.
The new corona inactivated vaccine developed by China Kexing Biotechnology has been tested in the final stage in Indonesia. 97% of vaccinators have produced antibodies, but its efficacy has not been determined.
The Russian authorities claim that the effective rate of the Sputnik V vaccine it has developed is 91.4% and that a large-scale vaccination campaign has already started.
The main characteristics of various European and American vaccines.
